Roche scores EU approval for at-home SMA treatment Evrysdi
Therapy indicated for use in SMA patients aged two months and older
Read More
Tag: risdiplam
EU regulators to review Evrysdi for SMA
The decision triggers a £15m milestone payment from Roche to PTC Therapeutics
Read More
Roche’s SMA treatment Evrysdi bags US approval
Drug cleared for use in SMA patients aged two months or older
Read More
Roche’s risdiplam shows promise in Type 1 SMA
Trial findings are particularly encouraging given that infants already had progressed disease
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
